Trillium Therapeutics ROA 2024

Trillium Therapeutics Aktienanalyse

What does Trillium Therapeutics do?

Trillium Therapeutics Inc is a Canadian biotech company specializing in the development of cancer treatments. The company was founded in 2005 and is based in Mississauga, Ontario. Trillium Therapeutics is involved in various areas of research. One of its key focuses is the development of immunotherapies for cancer treatment. The company is working on the discovery and development of novel targeted immunotherapies that aim to specifically target tumors and utilize the body's immune system to fight cancer. Another focus of Trillium Therapeutics is the development of cancer drugs targeting specific gene mutations. These drugs are intended to inhibit or kill cancer cells by specifically targeting the genetically altered cells. Trillium Therapeutics is also involved in the discovery and development of drugs for the treatment of immuno-oncological diseases, which are diseases where the body's immune system fights against its own cells, such as autoimmune diseases. The business model of Trillium Therapeutics is based on the research and development of innovative cancer drugs. The company collaborates closely with leading cancer centers and clinics to identify and test new therapeutic approaches. Trillium Therapeutics has a number of products and therapies in development. One example is TTI-621, an immunotherapy that aims to recognize and kill tumor cells. TTI-621 is currently in clinical trials for the treatment of T-cell lymphomas and glioblastomas, a type of brain tumor, and has shown promising results. Another product that Trillium Therapeutics is working on is TTI-622. It is also an immunotherapy that focuses on inhibiting T-cells to support controlled tumor growth. TTI-622 is currently in clinical trials in patients with advanced cancer. The company is also working on a number of preclinical programs aimed at expanding treatment options for cancer patients. These programs target various biological targets, including immunomodulation, induction of apoptosis, and inhibition of DNA repair. Trillium Therapeutics has received several awards and recognitions in recent years, including inclusion in the Russell 3000 Index, being named the top biotechnology company on the BioCentury Future Leaders List, and being recognized as one of the top 10 most exciting biotech companies in Canada. Overall, Trillium Therapeutics is a leading biotech company focused on the development of innovative cancer therapies. The company is at the forefront of technology and collaborates closely with leading cancer centers and clinics to develop products that can improve the lives of cancer patients. Trillium Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Trillium Therapeutics's Return on Assets (ROA)

Trillium Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Trillium Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Trillium Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Trillium Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Trillium Therapeutics Stock

What is the Return on Assets (ROA) of Trillium Therapeutics this year?

The Return on Assets (ROA) of Trillium Therapeutics is 0 undefined this year.

What was the ROA of Trillium Therapeutics compared to the previous year?

The ROA of Trillium Therapeutics has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of Trillium Therapeutics?

A high ROA is advantageous for investors of Trillium Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Trillium Therapeutics?

A low ROA can be unfavorable for investors of Trillium Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Trillium Therapeutics affect the company?

An increase in ROA of Trillium Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Trillium Therapeutics impact the company?

A reduction in the ROA of Trillium Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Trillium Therapeutics?

Some factors that can influence the ROA of Trillium Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Trillium Therapeutics important for investors?

The ROA of Trillium Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Trillium Therapeutics take to improve ROA?

To improve ROA, Trillium Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Trillium Therapeutics pay?

Over the past 12 months, Trillium Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Trillium Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Trillium Therapeutics?

The current dividend yield of Trillium Therapeutics is .

When does Trillium Therapeutics pay dividends?

Trillium Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Trillium Therapeutics?

Trillium Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Trillium Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Trillium Therapeutics located?

Trillium Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Trillium Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Trillium Therapeutics from 6/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/7/2024.

When did Trillium Therapeutics pay the last dividend?

The last dividend was paid out on 6/7/2024.

What was the dividend of Trillium Therapeutics in the year 2023?

In the year 2023, Trillium Therapeutics distributed 0 USD as dividends.

In which currency does Trillium Therapeutics pay out the dividend?

The dividends of Trillium Therapeutics are distributed in USD.